Net Loss Per Share

9 Months Ended

Sep. 30, 2020

Net Loss Per Share

Net Loss Per Share

13.          Net Loss Per Share

The following table sets forth the basic and diluted net loss per share computation and provides a reconciliation of the numerator and denominator for the periods presented:

	Three Months Ended				Nine Months Ended
(In thousands, except per share data)	September 30, 2020		September 30, 2019		September 30, 2020		September 30, 2019
Numerator:
Net loss attributable to CASI Pharmaceuticals, Inc.	$	(16,953)	$	(9,891)	$	(34,088)	$	(33,539)
Denominator:
Weighted average number of common shares		117,940		95,891		105,922		95,753
Denominator for basic and diluted net loss per share calculation		117,940		95,891		105,922		95,753
Net loss per share
— Basic and diluted	$	(0.14)	$	(0.10)	$	(0.32)	$	(0.35)

As of September 30, 2020, and 2019, outstanding stock options totaling 15,956,030 and 18,663,581, respectively, and outstanding warrants totaling 8,271,709 and 10,794,172, respectively, were anti-dilutive, and therefore, were not included in the computation of weighted average shares used in computing diluted loss per share.